MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

592

Employees592

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

592

Employees592

MNKD Key Statistics

Market cap

1.25B

Market cap1.25B

Price-Earnings ratio

-27.17

Price-Earnings ratio-27.17

Dividend yield

—

Dividend yield—

Average volume

5.28M

Average volume5.28M

High today

$3.94

High today$3.94

Low today

$3.84

Low today$3.84

Open price

$3.86

Open price$3.86

Volume

3.06M

Volume3.06M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$2.23

52 Week low$2.23

Stock Snapshot

The current MannKind(MNKD) stock price is $3.85, with a market capitalization of 1.25B. The stock trades at a price-to-earnings (P/E) ratio of -27.17.

On 2026-08-13, MannKind(MNKD) stock moved within a range of $3.84 to $3.94. With shares now at $3.85, the stock is trading +0.3% above its intraday low and -2.3% below the session's peak.

Trading activity shows a volume of 3.06M, compared to an average daily volume of 5.28M.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

MNKD News

Investing.com 2d

Mannkind director Steven Binder sells $158,547 in common stock - Investing.com

...

Simply Wall St 2d

Is MannKind Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?

MannKind (MNKD) recently drew investor attention after reporting positive topline Phase 1b INFLO-1 data for its inhaled nintedanib therapy in idiopathic pulmona...

Simply Wall St 5d

Why MannKind Is Up 5.1% After Positive Inhaled Nintedanib Data Despite Q2 Net Loss

MannKind Corporation recently reported its second-quarter 2026 results, with revenue rising to US$109.37 million from US$76.53 million a year earlier while movi...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More MNKD News

TipRanks 7d

MannKind price target lowered to $13 from $14 at Wells Fargo

Wells Fargo lowered the firm’s price target on MannKind (MNKD) to $13 from $14 and keeps an Overweight rating on the shares. The firm believes that good executi...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.